In brief: Genzyme; Novo Nordisk

By Staff Writers
Friday, 05 November, 2004

Genzyme will pay Wyeth US$121 million in cash for buy back rights to sell arthritis drug Synvisc in the United States and Europe. Genzyme said additional payments could extend until June 2012 for total payments of US$294 million.

Genzyme said it expects Synvisc to add about $240 million to its sales. It expects the deal to close in January.

Novo Nordisk shares rise on growth drug approval

Shares in Denmark's Novo Nordisk rose as much as 3 per cent on Thursday after the company's growth hormone drug Norditropin had been approved by US health authorities for use on adults.

The US Food and Drug Administration approved the drug Norditropin for adults after having granted approval for its use on children in October.

Related News

Oxytocin analogue treats chronic abdominal pain

Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...

'Low-risk' antibiotic linked to rise of dangerous superbug

A new study has challenged the long-held belief that rifaximin — commonly prescribed to...

Robotic hand helps cultivate baby corals for reef restoration

The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd